|
Programmed Cell Death Protein 1 Inhibitor Clinical Trials
1 actively recruiting trial
Also known as: PD-1 Inhibitor
Pipeline
Phase 2: 1
Top Sponsors
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences1
Indications
- Sintilimab1
- Concurrent Chemoradiotherapy1
- Locally Advanced Esophageal Squamous Cell Carcinoma1
- Immunonutrition1
- Radiotherapy1
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.